Verition Fund Management LLC Purchases 19,054 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Verition Fund Management LLC increased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 315.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,093 shares of the company's stock after acquiring an additional 19,054 shares during the quarter. Verition Fund Management LLC's holdings in Twist Bioscience were worth $1,134,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 856 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,730 shares of the business's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares of the company's stock, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 in the last quarter. 3.92% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on TWST shares. Robert W. Baird upped their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. Finally, Barclays cut their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Twist Bioscience Trading Up 3.9 %

Shares of TWST traded up $1.96 during mid-day trading on Friday, reaching $52.70. The company's stock had a trading volume of 512,209 shares, compared to its average volume of 941,345. Twist Bioscience Co. has a 1-year low of $24.81 and a 1-year high of $60.90. The business has a 50-day simple moving average of $44.36 and a two-hundred day simple moving average of $46.41. The stock has a market cap of $3.13 billion, a P/E ratio of -14.64 and a beta of 1.82.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.